ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0756

Stroke Characteristics in Giant Cell Arteritis and Takayasu Arteritis: A Multicenter Cohort Study of 108 Patients

Omar Dhrif1, Charlotte Caudron2, Simon Parreau3, Eric Liozon3, Adrien Mirouse4, Jean-François Alexandra5, Laurent Sailler6, Mathieu Groh7, Hubert De Boysson8, Mikael Ebbo9, Cloé Comarmond10, Cécile Audrey Durel11, Juliette Woessner12, Pierre-André Jarrot13, Kévin Didier14, Goulabchand Radjiv15, Cacoub Patrice16, Bernard Bonnotte17, David Saadoun16 and Maxime Samson1, 1CHU Dijon Bourgogne, Dijon, France, 2CENTRE HOSPITALIER UNIVERSITAIRE DE DIJON, Paris, France, 3CHU de Limoges, Limoges, France, 4Médecine Interne et Immunologie Clinique, Groupe Hospitalier Pitié-Salpêtrière, APHP, Paris, Paris, France, 5Internal Medicine, Hôpital Bichat, APHP, Paris, France, 6CHU Toulouse, Toulouse, France, 7Hôpital Foch, Suresnes, France, 8Internal Medicine, CHU Caean, Caen, France, 9Internal Medicine, Marseille-APHM, hôpital La Timone, Marseille, France, 10Department of Internal Medicine, Lariboisière University Hospital, Université Paris Cité, Assistance Publique Hôpitaux de Paris, INSERM U942, Paris, France, 11Médecine Interne, Hôpital Saint Joseph Saint Luc, Lyon, Lyon, France, 12Médecine Interne, CH d’Avignon, Avignon, Avignon, France, 13Médecine Interne, Hôpital de la Conception, APHM, Marseille, Marseille, France, 14Médecine Interne, CHU Reims, Reims, Reims, France, 15Médecine Interne, CHU Nîmes, Nîmes, Nîmes, France, 16Department of Internal Medicine and Clinical Immunology, Sorbonne Universités, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Centre national de références Maladies Autoimmunes et systémiques rares, Centre national de références Maladies Autoinflammatoires rares et Amylose inflammatoire (CEREMAIA), INSERM, UMR S959, Immunology-Immunopathology-Immunotherapy (I3), Paris, France, Paris, France, 17Internal medicine and clinical immunology, Université Bourgogne Europe , CHU Dijon Bourgogne, Dijon, France

Meeting: ACR Convergence 2025

Keywords: giant cell arteritis, Stroke, Takayasu.s arteritis, Vasculitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 26, 2025

Title: (0731–0764) Vasculitis – Non-ANCA-Associated & Related Disorders Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: In giant cell arteritis (GCA) and Takayasu arteritis (TA), strokes occur in approximately 7.4% and 15.8% of cases, respectively. Although these two large-vessel vasculitides share similarities, stroke presentation may differ in terms of clinical and radiological characteristics. This study aimed to compare the epidemiological, clinical, and prognostic features of stroke in patients with GCA and TA

Methods: This was a multicenter retrospective cohort study conducted in France, including patients meeting the 2022 ACR/EULAR classification criteria for GCA and either the 2022 ACR/EULAR criteria or modified Ishikawa criteria for TA. Eligible patients had at least one stroke confirmed by imaging, occurring either at the time of or within 4 weeks of vasculitis flare.

Results: A total of 108 patients (68 with GCA and 40 with TA) were analyzed. The female-to-male ratio was 0.78 in GCA and 5.2 in TA (p< 0.001). The mean age at stroke onset was 76+/-9 years in GCA and 35±10 years in TA (p< 0.001).At the time of stroke, cardiovascular risk factors in GCA versus TA were as follows: overweight (22.4% vs. 10.3%, p=0.174), obesity (7% vs. 2.6%, p=0.645), smoking (40.9% vs. 39.4%, p=0.885), hypertension (64.7% vs. 32.4%, RR=1.99, p=0.003), dyslipidemia (36.8% vs. 8.8%, RR=4.2, p=0.002), and diabetes (14.7% vs. 2.9%, p=0.095).Stroke occurred at the time of vasculitis diagnosis in 95.6% of GCA cases and 81.1% of TA cases (RR=1.18, p=0.031). All strokes were ischemic. The initial clinical presentation in GCA versus TA included motor deficits (47.1% vs. 30%, p=0.207), sensory deficits (14.7% vs. 16.7%, p=0.754), ophthalmologic symptoms (39.7% vs. 34.2%, p=0.677), cerebellar syndrome (29.4% vs. 0%, p=0.001), cranial nerve involvement (19.7% vs. 0%, p=0.017), language impairment (41.2% vs. 12.5%, RR=3.3, p=0.012), and neurosensory disturbances (55.9% vs. 18.4%, RR=3.04, p< 0.001).Strokes involved the carotid territory in 35.3% of GCA cases and in 79.5% of TA cases (RR=0.44, p< 0.001) while the vertebrobasilar territory was involved in 75% of GCA cases and 20.5% of TA cases (RR=3.7, p< 0.001). Stroke recurrence occurred in 14.7% of GCA cases and 7.5% of TA cases (p=0.364), with a median recurrence time of 6 months (IQR: 1–10 months) after the initial stroke. Vascular surgery was required in 6% of GCA cases and 41% of TA cases (RR=0.14, p< 0.001). The mean follow-up duration was 5 ± 6.1 years, with mortality rates of 14.5% in GCA and 5% in TA (p=0.194). The survival curve for both groups is presented in Figure 1.In multivariate analysis excluding age, independent factors associated with TA diagnosis were the absence of dyslipidemia (OR=0.085, p=0.035), carotid territory involvement (OR=13.7, p=0.003), and the need for vascular surgery (OR=10.6, p=0.009).

Conclusion: Stroke presentation differs between GCA and TA. In GCA, strokes predominantly affect older individuals with cardiovascular risk factors and mainly involve the vertebrobasilar territory. While in TA, carotid involvement is more frequent and often necessitates vascular intervention. These clinical and prognostic differences are crucial for optimizing patient management


Disclosures: O. Dhrif: None; C. Caudron: None; S. Parreau: None; E. Liozon: None; A. Mirouse: None; J. Alexandra: Chugai France, 2; L. Sailler: None; M. Groh: None; H. De Boysson: AbbVie/Abbott, 1, 2, Chugai, 2, Fresenius Kabi, 1, 2, Novartis, 2; M. Ebbo: None; C. Comarmond: Roche, 5; C. Durel: None; J. Woessner: None; P. Jarrot: None; K. Didier: None; G. Radjiv: None; C. Patrice: None; B. Bonnotte: Boehringer-Ingelheim, 2, Chugai, 2, Novartis, 2, Vifor Pharma, 2; D. Saadoun: None; M. Samson: AbbVie/Abbott, 2, AstraZeneca, 2, Boehringer-Ingelheim, 2, Chugai, 2, Fresenius Kabi, 2, GlaxoSmithKlein(GSK), 2, Novartis, 2, 5, Vifor Pharma, 2.

To cite this abstract in AMA style:

Dhrif O, Caudron C, Parreau S, Liozon E, Mirouse A, Alexandra J, Sailler L, Groh M, De Boysson H, Ebbo M, Comarmond C, Durel C, Woessner J, Jarrot P, Didier K, Radjiv G, Patrice C, Bonnotte B, Saadoun D, Samson M. Stroke Characteristics in Giant Cell Arteritis and Takayasu Arteritis: A Multicenter Cohort Study of 108 Patients [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/stroke-characteristics-in-giant-cell-arteritis-and-takayasu-arteritis-a-multicenter-cohort-study-of-108-patients/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/stroke-characteristics-in-giant-cell-arteritis-and-takayasu-arteritis-a-multicenter-cohort-study-of-108-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology